Lazard Freres Gestion S.A.S. Has $42.62 Million Position in IDEXX Laboratories, Inc. $IDXX

Lazard Freres Gestion S.A.S. lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.0% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 62,997 shares of the company’s stock after selling 15,702 shares during the period. Lazard Freres Gestion S.A.S.’s holdings in IDEXX Laboratories were worth $42,619,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in IDXX. Elyxium Wealth LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $3,666,459,000. Northwestern Mutual Wealth Management Co. raised its position in shares of IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after buying an additional 1,442,174 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of IDEXX Laboratories by 41.7% during the third quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock valued at $1,313,992,000 after buying an additional 605,290 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of IDEXX Laboratories by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after buying an additional 326,348 shares during the last quarter. Finally, Zurich Insurance Group Ltd FI acquired a new position in IDEXX Laboratories in the third quarter worth about $143,730,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $546.49 on Wednesday. The stock’s fifty day moving average is $569.38 and its 200-day moving average is $644.35. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The stock has a market capitalization of $43.11 billion, a PE ratio of 40.24, a PEG ratio of 3.17 and a beta of 1.58. IDEXX Laboratories, Inc. has a 52 week low of $496.61 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on IDXX shares. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Piper Sandler dropped their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Barclays dropped their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Finally, Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

Insider Buying and Selling at IDEXX Laboratories

In other news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the sale, the chief executive officer owned 83,606 shares in the company, valued at approximately $54,975,125.30. This represents a 21.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total value of $1,115,574.06. Following the sale, the executive vice president owned 18,141 shares in the company, valued at $11,511,734.37. The trade was a 8.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 27,777 shares of company stock worth $18,235,113 in the last 90 days. Company insiders own 0.79% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.